Evaluation of Antimicrobial Therapy Duration for Hospital-Acquired Pneumonia Treatment

Evaluation of Antimicrobial Therapy Duration for Hospital-Acquired Pneumonia Treatment Background The Infectious Diseases Society of America recommends a 7-day duration of antimicrobial therapy for hospital-acquired pneumonia (HAP); however, this recommendation is based on low-quality evidence. This recommendation is supported by evidence from ventilator-associated pneumonia clinical trials. Use of guideline-recommended antimicrobial durations is variable in clinical practice owing to the lack of literature available. Methods This was a retrospective, cohort, single-center study. Adult patients admitted with a diagnosis of HAP and received at least 72 hours of antimicrobial therapy were included. The primary outcome was day 7 clinical stability in patients treated with standard (≤7 days) compared with extended (>7 days) duration antimicrobial therapy. Secondary outcomes included hospital and intensive care unit length of stay (LOS), 30-day mortality, and 30-day hospital readmission rates. Results Fifty-three patient encounters were identified. Thirty-two patients (60.4%) received standard duration (6 [4.5–7] days) antimicrobial therapy, and 21 patients (39.6%) received extended duration (14 [11–14] days) antimicrobial therapy (P < 0.001). There were no statistically significant differences between groups with respect to day 7 clinical stability (62.5% vs 47.6%; P = 0.29), hospital LOS (9 [7–16] days vs 12 [7.5–24] days; P = 0.29), intensive care unit LOS (5 [3.5–9.5] days vs 5 [3–20] days; P = 0.62), 30-day mortality (3.1% vs 9.5%; P = 0.56), or 30-day readmission rates (21.9% vs 38.1%; P = 0.2). Conclusions No differences were observed in clinical outcomes between antimicrobial treatment groups. Guideline-recommended durations of antimicrobial therapy should be used in patients with HAP. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infectious Diseases in Clinical Practice Wolters Kluwer Health

Evaluation of Antimicrobial Therapy Duration for Hospital-Acquired Pneumonia Treatment

Loading next page...
1
 
/lp/wolters_kluwer/evaluation-of-antimicrobial-therapy-duration-for-hospital-acquired-3hoMlToZ3a
Publisher
Lippincott Williams & Wilkins
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1056-9103
eISSN
1536-9943
D.O.I.
10.1097/IPC.0000000000000577
Publisher site
See Article on Publisher Site

Abstract

Background The Infectious Diseases Society of America recommends a 7-day duration of antimicrobial therapy for hospital-acquired pneumonia (HAP); however, this recommendation is based on low-quality evidence. This recommendation is supported by evidence from ventilator-associated pneumonia clinical trials. Use of guideline-recommended antimicrobial durations is variable in clinical practice owing to the lack of literature available. Methods This was a retrospective, cohort, single-center study. Adult patients admitted with a diagnosis of HAP and received at least 72 hours of antimicrobial therapy were included. The primary outcome was day 7 clinical stability in patients treated with standard (≤7 days) compared with extended (>7 days) duration antimicrobial therapy. Secondary outcomes included hospital and intensive care unit length of stay (LOS), 30-day mortality, and 30-day hospital readmission rates. Results Fifty-three patient encounters were identified. Thirty-two patients (60.4%) received standard duration (6 [4.5–7] days) antimicrobial therapy, and 21 patients (39.6%) received extended duration (14 [11–14] days) antimicrobial therapy (P < 0.001). There were no statistically significant differences between groups with respect to day 7 clinical stability (62.5% vs 47.6%; P = 0.29), hospital LOS (9 [7–16] days vs 12 [7.5–24] days; P = 0.29), intensive care unit LOS (5 [3.5–9.5] days vs 5 [3–20] days; P = 0.62), 30-day mortality (3.1% vs 9.5%; P = 0.56), or 30-day readmission rates (21.9% vs 38.1%; P = 0.2). Conclusions No differences were observed in clinical outcomes between antimicrobial treatment groups. Guideline-recommended durations of antimicrobial therapy should be used in patients with HAP.

Journal

Infectious Diseases in Clinical PracticeWolters Kluwer Health

Published: Apr 1, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off